Brokerages Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Price Target at $11.00

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has received a consensus recommendation of “Buy” from the seven brokerages that are covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $11.00.

Several brokerages recently issued reports on AQST. Leerink Partners increased their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Friday. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, Cantor Fitzgerald started coverage on Aquestive Therapeutics in a research report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of large investors have recently bought and sold shares of the business. Victory Capital Management Inc. acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth about $27,000. nVerses Capital LLC purchased a new position in shares of Aquestive Therapeutics in the third quarter worth about $28,000. The Manufacturers Life Insurance Company purchased a new stake in Aquestive Therapeutics in the 2nd quarter valued at $76,000. Financial Advocates Investment Management increased its holdings in shares of Aquestive Therapeutics by 70.0% during the 2nd quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock worth $88,000 after buying an additional 14,000 shares during the last quarter. Finally, Harvey Capital Management Inc. purchased a new stake in Aquestive Therapeutics in the 3rd quarter valued at about $88,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Down 1.6 %

Shares of AQST stock opened at $3.59 on Friday. Aquestive Therapeutics has a 12-month low of $1.95 and a 12-month high of $6.23. The firm has a market cap of $327.33 million, a P/E ratio of -7.98 and a beta of 2.62. The business has a 50-day moving average price of $4.69 and a two-hundred day moving average price of $4.09.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to the consensus estimate of $12.69 million. During the same quarter in the previous year, the company posted ($0.03) EPS. As a group, research analysts expect that Aquestive Therapeutics will post -0.47 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.